Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Genitourinary 2Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiotherapy 43Temozolomide 34Magnetic Resonance Spectroscopy 33Doxorubicin 33Specimen Handling 31Cyclophosphamide 31Vincristine 24Etoposide 21Radiation 20Biopsy 20Ifosfamide 19Filgrastim 18Sirolimus 15Bevacizumab 15temsirolimus 14Sorafenib 13X-Rays 12Surgical Procedures, Operative 12Nivolumab 12Imatinib Mesylate 12Carboplatin 12Radiotherapy, Conformal 11Methotrexate 11Ipilimumab 11Vorinostat 10Peripheral Blood Stem Cell Transplantation 10Irinotecan 10Immunoglobulin G 10Disulfides 10Chemotherapy, Adjuvant 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × perifosine × Sarcoma × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00064324 2013-06-04

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡